目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapeutic area
1.2.2. Technology
1.2.3. Regional Scope
1.2.4. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapeutic area outlook
2.2.2. Technology outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Pharmacogenomics Technology Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape

Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis
4.1. Therapeutic Area Dashboard
4.2. Pharmacogenomics Technology Market: Therapeutic Area Movement Analysis
4.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
4.4. Oncology
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Lung Cancer
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Breast Cancer
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Colorectal Cancer
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Cervical Cancer
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Others
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Neurological Disorders
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cardiovascular Disorders
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Immunological Disorders
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Infectious Diseases
4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmacogenomics Technology Market: Technology Estimates & Trend Analysis
5.1. Technology Segment Dashboard
5.2. Pharmacogenomics Technology Market: Technology Movement Analysis
5.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
5.4. PCR
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. In-situ Hybridization
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Immunohistochemistry
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Sequencing
5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Others
5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Pharmacogenomics Technology Market by Region: Key Takeaways
6.4. North America
6.4.1. U.S.
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Mexico
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. France
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Italy
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. Spain
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Norway
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key country dynamics
6.5.7.2. Regulatory framework/ reimbursement structure
6.5.7.3. Competitive scenario
6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key country dynamics
6.5.8.2. Regulatory framework/ reimbursement structure
6.5.8.3. Competitive scenario
6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Australia
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Thailand
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Argentina
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/ reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key country dynamics
6.8.4.2. Regulatory framework/ reimbursement structure
6.8.4.3. Competitive scenario
6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. QIAGEN
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. GE HealthCare
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Agilent Technologies, Inc.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. F. Hoffmann-La Roche Ltd
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. FOUNDATION MEDICINE, INC
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Thermo Fisher Scientific Inc.
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Oxford Nanopore Technologies plc.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Twist Bioscience
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Leica Biosystems Nussloch GmBH
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Pfizer Inc
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Abbott
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives

List of Tables
Table 1. List of abbreviations
Table 2. Global pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 3. Global pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 4. Global pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 5. North America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 6. North America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 7. North America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 8. U.S. laboratory pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 9. U.S. pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 10. U.S. pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 11. Canada pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 12. Canada pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 13. Canada pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 14. Mexico pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 15. Mexico pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 16. Mexico pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 17. Europe pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 18. Europe pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 19. Europe pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 20. Germany pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 21. Germany pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 22. Germany pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 23. UK pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 24. UK pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 25. UK pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 26. France pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 27. France pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 28. France pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 29. Italy pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 30. Italy pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 31. Italy pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 32. Spain pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 33. Spain pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 34. Spain pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 35. Denmark pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 36. Denmark pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 37. Denmark pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 38. Sweden pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 39. Sweden pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 40. Sweden pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 41. Norway pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 42. Norway laboratory proficiency testing market, by technology, 2018 - 2030 (USD Million)
Table 43. Norway pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 44. Asia Pacific pharmacogenomics technology market, therapeutic area, 2018 - 2030 (USD Million)
Table 45. Asia Pacific pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 46. Asia Pacific pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 47. China pharmacogenomics technology market, therapeutic area, 2018 - 2030 (USD Million)
Table 48. China pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 49. China pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 50. Japan pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 51. Japan pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 52. Japan pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 53. India pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 54. India pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 55. India pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 56. South Korea pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 57. South Korea pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 58. South Korea pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 59. Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 60. Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 61. Australia pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 62. Thailand pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 63. Thailand pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 64. Thailand pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 65. Latin America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 66. Latin America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 67. Latin America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 68. Brazil pharmacogenomics technology, therapeutic area, 2018 - 2030 (USD Million)
Table 69. Brazil pharmacogenomics technology, by technology, 2018 - 2030 (USD Million)
Table 70. Brazil pharmacogenomics technology, by region, 2018 - 2030 (USD Million)
Table 71. Argentina pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 72. Argentina pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 73. Argentina pharmacogenomics technology market, by end region, 2018 - 2030 (USD Million)
Table 74. MEA pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 75. MEA pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 76. MEA pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 77. South Africa pharmacogenomics technology testing market, by therapeutic area, 2018 - 2030 (USD Million)
Table 78. South Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 79. South Africa pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 80. Saudi Arabia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 81. Saudi Arabia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 82. Saudi Arabia pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 83. UAE pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 84. UAE pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 85. UAE pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
Table 86. Kuwait pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
Table 87. Kuwait pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
Table 88. Kuwait pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Pharmacogenomics technology: market outlook
Fig. 10 Pharmacogenomics technology: competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 Pharmacogenomics technology market driver impact
Fig. 16 Pharmacogenomics technology market restraint impact
Fig. 17 Pharmacogenomics technology market strategic initiatives analysis
Fig. 18 Pharmacogenomics technology market: Therapeutic area analysis
Fig. 19 Pharmacogenomics technology market: Therapeutic area outlook and key takeaways
Fig. 20 Oncology market estimates and forecast, 2018 - 2030
Fig. 21 Neurological disorders market estimates and forecast, 2018 - 2030
Fig. 22 Cardiovascular diseases market estimates and forecast, 2018 - 2030
Fig. 23 Immunological disorders market estimates and forecast, 2018 - 2030
Fig. 24 Infectious diseases market estimates and forecast, 2018 - 2030
Fig. 25 Others market estimates and forecast, 2018 - 2030
Fig. 26 Pharmacogenomics technology market: Technology movement analysis
Fig. 27 Pharmacogenomics technology market: Technology outlook and key takeaways
Fig. 28 PCR market estimates and forecasts, 2018 - 2030
Fig. 29 In-situ hybridization market estimates and forecasts, 2018 - 2030
Fig. 30 Immunohistochemistry market estimates and forecasts, 2018 - 2030
Fig. 31 Sequencing market estimates and forecasts, 2018 - 2030
Fig. 32 Others market estimates and forecasts, 2018 - 2030
Fig. 33 Global Pharmacogenomics technology market: Regional movement analysis
Fig. 34 Global Pharmacogenomics technology market: Regional outlook and key takeaways
Fig. 35 North America market estimates and forecasts, 2018 - 2030
Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
Fig. 37 Canada market estimates and forecasts, 2018 - 2030
Fig. 38 Mexico market estimates and forecasts, 2018 - 2030
Fig. 39 Europe market estimates and forecasts, 2018 - 2030
Fig. 40 UK market estimates and forecasts, 2018 - 2030
Fig. 41 Germany market estimates and forecasts, 2018 - 2030
Fig. 42 France market estimates and forecasts, 2018 - 2030
Fig. 43 Italy market estimates and forecasts, 2018 - 2030
Fig. 44 Spain market estimates and forecasts, 2018 - 2030
Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
Fig. 46 Sweden market estimates and forecasts, 2018 - 2030
Fig. 47 Norway market estimates and forecasts, 2018 - 2030
Fig. 48 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 49 China market estimates and forecasts, 2018 - 2030
Fig. 50 Japan market estimates and forecasts, 2018 - 2030
Fig. 51 India market estimates and forecasts, 2018 - 2030
Fig. 52 Thailand market estimates and forecasts, 2018 - 2030
Fig. 53 South Korea market estimates and forecasts, 2018 - 2030
Fig. 54 Australia market estimates and forecasts, 2018 - 2030
Fig. 55 Latin America market estimates and forecasts, 2018 - 2030
Fig. 56 Brazil market estimates and forecasts, 2018 - 2030
Fig. 57 Argentina market estimates and forecasts, 2018 - 2030
Fig. 58 Middle East and Africa market estimates and forecasts, 2018 - 2030
Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
Fig. 60 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 61 UAE market estimates and forecasts, 2018 - 2030
Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030